- Home
- DFNS vs RDHL Comparison
DFNS vs RDHL Comparison
Compare DFNS & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DFNS | RDHL |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.7M |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | DFNS | RDHL |
|---|---|---|
| Price | $1.98 | $0.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | ★ $65.00 | N/A |
| AVG Volume (30 Days) | 479.6K | ★ 869.8K |
| Earning Date | 11-17-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 261.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,913,461.00 | N/A |
| Revenue This Year | N/A | $17,592.31 |
| Revenue Next Year | $33.09 | $25.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.82 | $0.38 |
| 52 Week High | $335.00 | $1.60 |
Technical Indicators
Market Signals| Indicator | DFNS | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 22.59 | 43.31 |
| Support Level | N/A | $0.38 |
| Resistance Level | $7.36 | $0.71 |
| Average True Range (ATR) | 0.44 | 0.04 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 0.76 | 35.77 |
Price Performance
Historical ComparisonAbout DFNS T3 Defense Inc. Common Stock
T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. The company operates as a strategic platform, building a portfolio of mission-critical suppliers and technology companies. Its portfolio includes businesses involved in defense and aerospace technologies, such as AI software, unmanned aerial systems, electro-mechanical manufacturing, and motion control systems, as well as activities in technology distribution, licensing, and defense infrastructure development through joint ventures.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.